AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04168892 — intervention group
Intervention type: DRUG
Intervention: 225 IU of HMG in patients with age > 35 years
Description: The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
Study NCT00886509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: s.c. administration of pegylated G-CSF over 6 months
Study NCT00886509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control Arm 1: Collateral promotion; PCI after 6 months
Study NCT06383455 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical periodontal therapy
Description: An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.
Study NCT01561716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii Fit
Description: This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
Study NCT02690038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Description: Baseline Ig \< 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization
Study NCT02690038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization
Study NCT00307398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Description: One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
Study NCT00307398 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
Study NCT00356525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
Study NCT00356525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
Study NCT00356525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
Study NCT01196416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01196416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01196416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01196416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01196416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT01196416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study NCT02823379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: A Smartphone delivered physical activity program
Study NCT02823379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
Study NCT03507010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
Study NCT03507010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Radiotherapy
Description: Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
Study NCT03202134 — intervention group
Intervention type: OTHER
Intervention: opioid free anesthesia
Description: general anesthesia blocking reflexes without using an opioid
Study NCT00315016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: active comparator
Study NCT03825848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans jugular intrahepatic portal systemic shunt
Description: Shunting left or right PV branch in the TIPS procedure
Study NCT04491591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction Education and Support Tool (BREASTChoice)
Description: The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
Study NCT04491591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Website
Description: -(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
Study NCT04491591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Survey
Description: -Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
Study NCT04391192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Overdose Response
Description: All participants will be provided the phone number and encouraged to call when they use alone.
Study NCT04372121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04372121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04372121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Description: For oral administration once daily
Study NCT04372121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04372121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04372121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study NCT01784081 — intervention group
Intervention type: OTHER
Intervention: Palliative care with decision aids
Description: Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
Study NCT01526343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal XT implantation
Description: The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
Study NCT01682343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Milk-calcium supplement
Study NCT00719706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetyl-l-carnitine PLUS alpha-lipoic acide
Description: 1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
Study NCT00719706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04914650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
Study NCT02131142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom drug coated coronary stent
Description: Placement of a BioFreedom drug coated stent in a narrow coronary artery
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BA (brief advice)
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA (brief advice)
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BA (brief advice)
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE (supervised and home-based exercise)
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHE (supervised and home-based exercise)
Study NCT00356525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
Study NCT01656980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
Study NCT01656980 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tumor resection surgery
Description: For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
Study NCT02848209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCA 20% Peeling
Description: TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
Study NCT02848209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phenol/croton oil Peeling
Description: Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
Study NCT02848209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCA 40% Peeling
Description: TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
Study NCT04177407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
Description: Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
Study NCT03639779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
Study NCT03639779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
Study NCT03633825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief help-seeking barrier reduction intervention
Description: The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
Study NCT03766815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA 200mg/kg/day
Description: BCAA supplement based on 200mg/kg/day for 18 days.
Study NCT03766815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fiber supplement jelly for 18 days.
Study NCT03766815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA 400mg/kg/day
Description: BCAA supplement based on 400mg/kg/day for 18 days.
Study NCT03766815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle damaging exercise
Description: Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
Study NCT03766815 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Muscle damaging exercise
Description: Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
Study NCT04030208 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Umbulizer
Description: Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
Study NCT04030208 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Mechanical Ventilator
Description: A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
Study NCT02501928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 4 mg
Description: Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
Study NCT02501928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine PR 8 mg
Description: Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
Study NCT02501928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 2 mg
Description: Fesoterodine BIC 2 mg tablet once daily for 28 weeks
Study NCT02501928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine BIC 4 mg
Description: Fesoterodine BIC 4 mg tablet once daily for 28 weeks
Study NCT04445831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-35.030
Description: Administration of a Low dose of ACI-35.030
Study NCT04445831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-35.030
Description: Administration of a Medium dose of ACI-35.030
Study NCT04445831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-35.030
Description: Administration of a High dose of ACI-35.030
Study NCT04445831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo
Study NCT04445831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JACI-35.054
Description: Administration of a Low dose of JACI-35.054
Study NCT04445831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JACI-35.054
Description: Administration of a Medium dose of JACI-35.054
Study NCT02836925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir+Sofosbuvir
Description: Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options
Study NCT02836925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir+Velpatasvir
Description: Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment
Study NCT01007305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral salpingo-oophorectomy
Description: Removal of both ovaries and fallopian tubes at the time of hysterectomy
Study NCT01007305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian conservation
Description: Both ovaries and fallopian tubes not removed at the time of hysterectomy
Study NCT03719625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
Study NCT03719625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
Study NCT03454503 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: Film coated tablet contains 400 mg imatinib (as mesilate)
Study NCT02480101 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 live influenza vaccine
Description: H7N9 live influenza vaccine
Study NCT02480101 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized purified allantoic fluid of chicken embryos with stabilizers
Study NCT03583307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
Study NCT02370238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
Study NCT02370238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
Study NCT02370238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
Study NCT02370238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
Study NCT00512122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withholding PN during the first week of ICU stay
Description: Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
Study NCT00512122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E
Description: PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
Study NCT01867892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT
Description: oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
Study NCT01867892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
Description: Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
Study NCT01113593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Inhalation solution
Study NCT01860274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Mesh for vein grafts
Study NCT03478722 — intervention group
Intervention type: OTHER
Intervention: Protein Meal
Description: Ingestion of mixed meal containing 20 g of dietary protein
Study NCT03478722 — intervention group
Intervention type: OTHER
Intervention: Stable Isotope Amino Acid Infusion
Description: Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
Study NCT00799058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapivirine 4789
Description: dapivirine gel 4789, 0.05%, 2.5g applied once daily
Study NCT02986620 — intervention group
Intervention type: GENETIC
Intervention: IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
Description: Observation of the test result.
Study NCT04216875 — intervention group
Intervention type: PROCEDURE
Intervention: Best Practice Diabetes Management in Primary Care
Description: Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
Study NCT00799058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapivirine gel 4759
Description: dapivirine gel 4759, 0.05%, 2.5g applied once daily